Postmenopausal Osteoporosis Market Growth Accelerated by Rising Demand for Bone Health Medications
Postmenopausal Osteoporosis Market |
Postmenopausal osteoporosis occurs in women after menopause when estrogen levels drop sharply. It is a condition that weakens bones and makes them fragile. Medications such as bisphosphonates, estrogen therapy, selective estrogen receptor modulators, and monoclonal antibodies are prescribed by physicians to treat osteoporosis and prevent fractures.
The global
Postmenopausal Osteoporosis Market is estimated to be valued at US$ 4747.9 Mn
in 2023 and is expected to exhibit a CAGR of 67. % over the forecast period
2023 to 2030, as highlighted in a new report published by Coherent Market
Insights.
Market key trends:
The rising demand for bone health medications is one of the key trends driving
the growth of the postmenopausal osteoporosis market. As more women are
diagnosed with osteoporosis after menopause, the consumption of medications
such as bisphosphonates and selective estrogen receptor modulators has been
increasing steadily. These drugs not only help strengthen bones but also reduce
the risk of fractures caused by osteoporosis. Manufacturers are also focusing
on developing novel medications with improved efficacy and safety profiles
which is anticipated to further fuel the market growth over the forecast
period.
Segment
Analysis
The global postmenopausal osteoporosis market is dominated by the
bisphosphonates sub segment due to its higher efficacy and safer side effect
profile compared to other available drugs in the market. Bisphosphonates
directly inhibit bone resorption by binding to calcium phosphate crystals in
the bone, and also induce apoptosis in osteoclasts.
Key Takeaways
Global
Postmenopausal Osteoporosis Market Size is expected to witness high
growth.
Comments
Post a Comment